SPC3, an anti-HIV peptide construct derived from the viral envelope, binds and enters HIV target cells

Journal of Peptide Science

Volumn 4, Issue 8, 1998, Pages 479-485

  Barbouche, Rym ^a   Miquelis, Raymond ^a   Sabatier, Jean Marc ^a   Fenouillet, Emmanuel ^a  

^a CNRS   (France)

Author keywords

Anti HIV agent; Env derived peptide; HIV infection; SPC3; V3 domain

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

ANTIVIRUS AGENT; GLYCOPROTEIN GP 120; RECOMBINANT PROTEIN; SPC3 PEPTIDE; VIRUS ENVELOPE PROTEIN;

ARTICLE; CD4+ T LYMPHOCYTE; CELL LINE; CHEMISTRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; METABOLISM; SURFACE PROPERTY; SYNTHESIS; VIROLOGY;

ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; GENE PRODUCTS, ENV; HIV; HIV ENVELOPE PROTEIN GP120; HUMANS; RECOMBINANT PROTEINS; SURFACE PROPERTIES;

EID: 0032249583     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1099-1387(199812)4:8<479::aid-psc167>3.0.co;2-i     Document Type: Article

References (21)

1. J.P. Moore, B.A. Jameson, R.A. Weiss and Q. Sattentau. The HIV-cell fusion reaction, in: Viral Fusion Mechanisms, J. Bentz, Ed., p. 230-289, CRC Press 1993.
2. J.P. Moore and P.L. Nara (1991). The role of the V3 loop of gp120 in HIV infection. AIDS 5, 21-33.
3. M. Autiero, P. Abrescia, M. Dettin, C. Di Bello and J. Guardiola (1991). Binding to CD4 of synthetic peptides patterned on the principal neutralizing domain of HIV-1 envelope protein. Virology 185, 820-828.
4. M.P. D'Souza and V.A. Harden (1996). Chemokines and HIV-1 second receptors. Nature Medecine 2, 1293-1300.
5. C. Callebaut, E. Jacotot, G. Guichard, B. Krust, M.-A. Rey-Cuille, D. Cointe, N. Benkirane, J. Blanco, S. Muller, J.P. Briand and A. Hovanessian (1996). Inhibition of HIV infection by pseudopeptides blocking viral envelope glycoprotein-mediated membrane fusion and cell death. Virology 218, 181-192.
6. 3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages. J. Virol. 68, 5714-5720.
7. 3 loop of envelope glycoprotein gp 120 inhibit human immunodeficiency virus type 1 infection through interaction with CD4. Virology 206, 457-465.
8. - cells by two distincts mechanisms. Proc. Natl. Acad. Sci. USA 92, 4867-4871.
9. R.B. Merrifield (1986). Solid phase peptide synthesis. Science 232, 341-347.
10. J.M. Sabatier, K. Mabrouk, M. Moulard, H. Rochat, J. Van Rietschoten and E. Fenouillet (1996). Anti-HIV activity of multibranched peptide constructs derived either from the cleavage sequence or from the transmembrane domain (gp41) of the human immunodeficiency virus type 1 envelope. Virology 223, 406-408.
11. J.S. Mc Dougal, S.P. Cort, M.S. Kennedy, C.D. Cabradilla, P.M. Feorino, D.P. Francis, D. Hicks, V.S. Kalyanaraman and L.S. Martin (1985). Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy-associated virus (LAV). J. Immunol. Methods 76, 171-177.
12. R. Gabathuler, J. Alimonti, Q.J. Zhang, G. Kolaitis, G. Reid and W.A. Jefferies (1998). Surrogate antigen processing mediated by TAP-dependent antigenic peptide secretion. J. Cell. Biol. 140, 17-27.
13. 3, an Env-derived peptide drug under phase II clinical trials. J. Peptide Res., in press.
14. R. Barbouche, J.M. Sabatier, E. Fenouillet (1998). An anti-HIV peptide construct derived from the cleavage region of Env acts on Env fusogenicity through the presence of a functional cleavage sequence. Virology, in press.
15. G. Karsenty, M. Michel-Béchet and J. Charreire (1985). Monoclonal human thyroid cell line GEJ expressing human thyrotropin receptors. Proc. Natl. Acad. Sci. USA 82, 2120-2124.
16. M. Nomizu, K. Yamamura, H.K. Kleinman and Y. Yamada (1993). Multimeric forms of Tyr-Ile-Gly-Ser-Arg peptide enhance the inhibition of tumor growth and metastasis. Cancer Res. 53, 3459-3461.
17. A.A. Scheel and H.R. Pelham (1996). Purification and characterization of the human KDEL receptor. Biochemistry 35, 10203-10209.
18. D.W. Wilson, M.J. Lewis and R.B. Pelham (1993). pH-dependent binding of KDEL to its receptor in vitro. J. Biol. Chem. 268, 7465-7468.
19. A. De Rossi, M. Pasti, F. Mammano, M. Panozzo, M. Dettin, C. Di Bello and L. Chieco-Bianchi (1991). Synthetic peptides from the principal neutralizing domain of human immunodeficiency virus type 1 (HIV-1) enhance HIV-1 infection through a CD4-dependent mechanism. Virology 184, 187-196.
20. W.A. Banks, V. Akerstrom, A.J. Kastin (1998). Adsorptive endocytosis mediates the passage of HIV-1 across the blood brain barrier: evidence for a post-internalization coreceptor. J. Cell.Sci. 111, 533-540.
21. S. Hallenberger, V. Bosch, H. Angliker, E. Shaw, H.D. Klenk and W. Garten (1992). Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 360, 358-361.